Last updated: February 13, 2026
What is the current market status of drug NDC 70165-0015?
The drug identified by NDC 70165-0015 is Erenumab, marketed as Aimovig by Novartis. It is a monoclonal antibody used for the preventive treatment of migraine in adult patients. Since its FDA approval in May 2018, Aimovig has established a significant presence in migraine prophylaxis.
The drug’s market penetration has grown steadily. As of 2023, Aimovig maintains a leading position within the calcitonin gene-related peptide (CGRP) inhibitor class. Market share data indicates approximately 60-65% within this category, with sales figures surpassing $600 million globally in 2022.
The competitive landscape includes other CGRP inhibitors such as Ajovy (Teva) and Emgality (Eli Lilly). The overall migraine preventive market size is estimated at $2-3 billion annually, with Aimovig accounting for a substantial segment.
What are the key factors influencing the market?
-
FDA approval status and label updates: Claims of efficacy, safety profiles, and expanded indications influence prescribing trends. In May 2022, FDA approved Aimovig for pediatric patients aged 6-17, broadening the target population.
-
Pricing and reimbursement policies: The average wholesale price (AWP) for Aimovig is approximately $6,000 per year per patient. Commercial payer coverage is high, but patient co-pays can limit access.
-
Competition: The emergence of biosimilars or next-generation CGRP inhibitors could impact sales. As of 2023, biosimilar entries are not yet available, but pipeline drugs and oral CGRP antagonists (like ubrogepant) influence market dynamics.
-
Patent status: Novartis's patent for Aimovig is expected to extend into 2028-2030, providing market exclusivity for the foreseeable future.
How are price projections evolving?
Price projections suggest moderate stability through 2025, given regulatory and patent protections. However, potential shifts include:
-
Price Erosion: Competitive pressures may lead to discounts or value-based pricing agreements. A decline of 10-15% annually in list price has been observed in some markets over the past two years.
-
Market Expansion: Expanded FDA indications for pediatric and preventive use could increase patient uptake, supporting revenue growth.
-
Reimbursement Reforms: Changes in payer policies, such as increased use of prior authorization and value-based agreements, might influence net pricing.
Forecasted revenue estimates for 2023-2027
| Year |
Revenue (USD millions) |
Notes |
| 2023 |
600 - 700 |
Maintains strong market presence |
| 2024 |
550 - 650 |
Slight decline due to competitive pressures |
| 2025 |
500 - 600 |
Potential market saturation |
| 2026 |
450 - 550 |
Patent protection continues, possible biosimilar threat unlikely |
| 2027 |
400 - 500 |
Approaching patent expiry, increased biosimilar risk |
Are there emerging pathways influencing pricing?
Several factors could impact pricing trajectories:
-
Biosimilar development: No biosimilars for Aimovig currently in late-stage development. Once approved, they could prompt significant price reductions.
-
Oral CGRP antagonists: Ortoghonal molecules like ubrogepant, delivered orally, may limit the long-term growth of injectable CGRP inhibitors.
-
Regulatory environment: Payers are increasingly adopting value-based reimbursement models, potentially limiting reimbursement rates.
What are the risks to market stability?
-
Patent litigation or patent expiry: Patent challenges or expirations around 2028-2030 could open the market to biosimilars or generics.
-
Clinical efficacy and safety data: Negative data could reduce prescribing or lead to label restrictions.
-
Pricing politics: Increased pressure for drug price regulation could lower prices.
Summary of key data points
| Aspect |
Data |
| Current market size |
Estimated at $600 million globally in 2022 |
| Market share |
Approximately 60-65% within CGRP class |
| Price per patient/year |
Around $6,000 |
| Patent expiration |
2028-2030 (expected, subject to patent litigation) |
| Competitors |
Ajovy, Emgality, pipeline oral CGRP antagonists |
| Regulatory updates |
Pediatric approval (2022), expanding target population |
Key Takeaways
- Aimovig remains a leading CGRP inhibitor with stable revenues driven by high efficacy and payer coverage.
- Market growth will hinge on regulatory approvals, competitive entries, and pricing strategies.
- Patent protections provide revenue stability into the late 2020s, but upcoming biosimilar and generic entries could induce price erosion.
- Reimbursement policies and value-based contracting will be crucial factors influencing net prices.
- Emerging oral treatments may challenge injectable CGRP inhibitors, affecting future market size.
FAQs
1. How will patent expirations affect Aimovig's pricing?
Patent expiry around 2028-2030 could lead to biosimilar competition, likely causing significant price reductions and revenue decline.
2. What is the primary driver of Aimovig's revenue growth?
Expanded indications and increased patient access support growth, assuming stable pricing and continued market dominance.
3. How does Aimovig compare to competitors?
It holds roughly 60-65% of the CGRP inhibitor market share, with similar efficacy but potentially differentiated by safety profiles and payer coverage.
4. Are biosimilars imminent?
No biosimilars for Aimovig are in late-stage development as of 2023, but biosimilar competition is expected post-2030.
5. What market factors could disrupt the current pricing projections?
Introduction of biosimilars, regulatory price controls, or shifts in clinical practice toward oral alternatives could reduce prices and market size.
References:
- Novartis Annual Report 2022.
- FDA Approval Records, Aimovig.
- IQVIA Prescription Data 2022.
- Market Research Future, “Migraine Therapeutics Market,” 2023.
- U.S. Patent and Trademark Office, Patent Status Reports.
